Datapoint: FDA Expands HAE Nod for Takeda’s Takhzyro

Takeda’s Takhzyro last week won expanded use as a prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients age 2 to 12. The injectable was previously approved in patients 12 and older. For that indication, Takhzyro holds covered or better status for 95% of all insured lives under the medical benefit. It is covered for just 15% of insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 2/6/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today